← Product Code [DAK](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DAK) · K032254 # IBL C1Q-CIC CIA TEST (K032254) _Ibl GmbH · DAK · Aug 29, 2003 · Immunology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DAK/K032254 ## Device Facts - **Applicant:** Ibl GmbH - **Product Code:** [DAK](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DAK.md) - **Decision Date:** Aug 29, 2003 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.5240 - **Device Class:** Class 2 - **Review Panel:** Immunology ## Indications for Use The IBL-C1q-CIC test is a quantitative enzyme immunoassay for the in vitro diagnostic detection of circulating immune complex that bind C1q in serum. The measurement is performed as an aid in the diagnosis of various autoimmune and other CIC related diseases. Levels of these complexes are one indicator in a multi-factorial diagnostic regime. ## Device Story The IBL C1q-CIC EIA is a quantitative enzyme immunoassay (EIA) used to detect circulating immune complexes (CIC) in human serum. The device functions by measuring the binding of CIC to C1q. It is intended for use in clinical laboratory settings by trained laboratory personnel. The output is a quantitative measurement of CIC levels, which serves as one indicator within a multi-factorial diagnostic regime for autoimmune and CIC-related diseases. The test assists clinicians in the diagnostic process by providing objective data on immune complex levels. ## Clinical Evidence No clinical studies were performed. Evidence consists of analytical performance and method comparison. Precision studies (intra-assay CV 7.6-10.7%, inter-assay CV 5.4-15.5%) and method comparison against the predicate (N=80) showed 93.7% relative sensitivity, 98.4% relative specificity, and 97.5% overall agreement. Analytical specificity confirmed no interference from bilirubin, hemoglobin, or EDTA. Detection limit is 10 ug/mL. ## Technological Characteristics Solid-phase ELISA; sandwich principle. Components: monoclonal anti-C1q antibody-coated microtiter plates, monoclonal anti-human IgG-HRP conjugate, TMB substrate. Requires microtiter plate reader (450 nm). Manual assay format. Serum sample matrix. ## Regulatory Identification A complement components immunological test system is a device that consists of the reagents used to measure by immunochemical techniques complement components C1q , C1r , C1s , C2 , C3 , C4 , C5 , C6 , C7 , C8 , and C9 , in serum, other body fluids, and tissues. Complement is a group of serum proteins which destroy infectious agents. Measurements of these proteins aids in the diagnosis of immunologic disorders, especially those associated with deficiencies of complement components. ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY A. 510(k) Number: K032254 B. Analyte: Circulating Immune Complex C. Type of Test: Quantitative, ELISA D. Applicant: Immuno-Biological Laboratories (IBL) E. Proprietary and Established Names: IBL C1q-CIC EIA Test F. Regulatory Information: 1. Regulation section: 21CFR 866.5240 2. Classification: Complement C1q, Antigen, Antiserum, Control 3. Product Code: DAK 4. Panel: 82 Immunology G. Intended Use: 1. Indication(s) for use: The IBL-C1q-CIC test is a quantitative enzyme immunoassay for the in vitro diagnostic detection of circulating immune complex that bind C1q in serum. The measurement is performed as an aid in the diagnosis of various autoimmune and other CIC related diseases. Levels of these complexes are one indicator in a multi-factorial diagnostic regime. 2. Special condition for use statement(s): NA 3. Special instrument Requirements: Microtiter plate reader capable of reading absorbance at 450 nm (reference wavelength 600-650 nm) H. Device Description: The in vitro diagnostic reagent kit contains sufficient reagents for 96 determinations. The reagent consist of the following: 4 each of 3 x 8 antibody coated microwells, 1 vial of ready to use calibrator, 1 vial each of positive and negative controls, 1 vial of ready to use enzyme conjugate, 1 bottle each of ready to use TMB substrate solution and stop solution, 1 bottle of Wash buffer and Sample Diluent. I. Substantial Equivalence Information: 1. Predicate device name(s): Scimedx C1q-CIC EIA 2. Predicate K number(s): {1} Page 2 of 4 K833636 3. Comparison with predicate: | Similarities | | | | --- | --- | --- | | Item | Device | Predicate | | Intended Use | Quantitative enzyme immunoassay for the in vitro diagnostic detection of C1q - circulating immune complex in human serum | Same | | Sample Preparation | 1:5 sample dilution | Same | | Sample | Serum Only | Same | | Component | Monoclonal anti-C1q Antibody coated microplate; Monoclonal Anti-Human IgG-HRP conjugate | Same | | Reagent Volumes | 100 uL Sample diluent 100 uL per well | Same | | Differences | | | | Item | Device | Predicate | | Cut-Off | Negative = <40 ug/mL Equiv. = 40-50 ug/mL Positive >50 ug/mL | Negative 0-34 ug/mL Positive >35 ug/mL | | Standards and Controls | Liquid positive and negative controls and 1 level of standard | Lyophilized Positive and negative controls and 3 levels of standards | | Incubation Time | 30 min/15 min/ 15 min @ R.T. | 60 min/ 60 min/ 30 min @32-37°C/R.T./R.T. | J. Standard/Guidance Document Referenced (if applicable): NA K. Test Principle: Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. The wells are coated with an antibody, directed towards an epitope of an antigen molecule. The antigen of the sample is incubated in the coated well with enzyme conjugated second antibody (E-Ab), directed towards a different region of the antigen molecule. After the substrate reaction, the intensity of the developed color is proportional to the amount of the antigen. Results of samples can be determined directly using the standard curve. L. Performance Characteristics (if/when applicable): 1. Analytical performance: a. Precision/Reproducibility: Studies were performed using 5 sera samples, 4 positives and 1 negative. {2} Page 3 of 4 ## Intra-Assay | N | mean | CV% | | --- | --- | --- | | 8 | 6.7 | 10.7 | | 8 | 64.0 | 9.2 | | 8 | 81.9 | 7.6 | | 8 | 86.0 | 8.7 | | 8 | 114.9 | 8.1 | ## Inter-Assay | N | mean | CV% | | --- | --- | --- | | 12 | 6.4 | 15.5 | | 12 | 64.8 | 5.4 | | 12 | 82.6 | 8.1 | | 12 | 88.3 | 9.4 | | 12 | 117.6 | 6.8 | b. Linearity/assay reportable range: No negative hook effect was observed through the OD range. c. Traceability (controls, calibrators, or method): The value of the standards was determined against the predicate Scimedx kit. An optimal level of 100 ug/mL was used. New batch of standards were tested against previously approved batches. Controls were run in the assay, typically on three batches of plates, and assign an acceptable range based on the mean +/- 2 standard deviations. d. Detection limit: 2 X SD of zero standard = 10 ug/mL e. Analytical specificity: Bilirubin up to 0.25 g/L, hemoglobin up to 10 g/L and EDTA up to 10 mM do not have a significant effect on the test results. A statement regarding potential interferences (heterophile antibodies) is included in the Limitations Section. f. Assay cut-off: <40 ug/mL The grey zone was established on the basis of 2 and 3 SDs of the mean of the normal population. ROC analysis was also performed, with the summary results shown in the following table: | Assay Upper limit | 100 | | --- | --- | | Cut-off Increment | 1 | | N^{0} Negatives | 44 | | N^{0} Positives | 16 | | Suggested Cut-off | 38.0 | | Sensitivity | 93.75% | {3} Page 4 of 4 | Specificity | 90.91% | | --- | --- | 2. Comparison studies: a. Method comparison with predicate device: | | Scimedx C1q-CIC | | | | --- | --- | --- | --- | | IBL C1q-CIC | positive | negative | total | | Positive | 15 | 1 | 16 | | Negative | 1 | 63 | 64 | | Total | 16 | 64 | | Relative Sensitivity = 93.7% Relative Specificity = 98.4% Overall agreement = 97.5% b. Matrix comparison: Both tests use serum only 3. Clinical studies: a. Clinical sensitivity: NA b. Clinical specificity: NA c. Other clinical supportive data (when a and b are not applicable): NA 4. Clinical cut-off: NA 5. Expected values/Reference range: C1q (ug/mL) Negative $= < 40$ Equivocal $= 40 - 50$ Positive $= >50$ M. Conclusion: Based upon the review of the information provided in this 510(k), The IBL C1q-CIC test appears to be Substantially Equivalent to devices regulated under 21CFR 866.5240, product code DAK, Immunology Devices Panel 82, Class II. --- **Source:** [https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DAK/K032254](https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DAK/K032254) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com